New Short-Duration therapy aims to control rare blood cancer
NCT ID NCT07169565
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times
Summary
This early-phase study tests a time-limited combination of three drugs (ibrutinib, bendamustine, and rituximab) in people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to find the safest dose and see if a fixed course of treatment can control the disease without needing lifelong medication. About 21 adults aged 18 to 75 with a specific genetic mutation (MYD88 L265P) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.